LB Pharmaceuticals Inc Common Stock (LBRX) quarterly balance sheet — complete assets, liabilities & equity history
| Total Current Assets | 389.07M | 308.43M | 316.4M | 14.78M | 14.78M | 74.19M |
| Cash & Short-Term Investments | 365.64M | 295.21M | 314.48M | 14.22M | 14.22M | 72.13M |
| Cash Only | 320.68M | 250.17M | 269.74M | 14.22M | 14.22M | 17.63M |
| Short-Term Investments | 44.96M | 45.04M | 44.73M | 0 | 0 | 54.49M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 20.8M | 11.23M | 1.92M | 556K | 0 | 10K |
| Total Non-Current Assets | 4.41M | 4.5M | 4.34M | 4.47M | 4.47M | 67K |
| Property, Plant & Equipment | 3.63M | 3.73M | 3.83M | 3.96M | 3.96M | 67K |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 776K | 770K | 512K | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 508K | 508K | 0 |
| Total Assets | 393.48M | 312.93M | 320.75M | 19.25M | 19.25M | 74.26M |
| Asset Turnover | - | - | - | - | - | - |
| Asset Growth % | 1944.27% | - | - | - | -74.08% | - |
| Total Current Liabilities | 10.91M | 7.44M | 6.65M | 3.91M | 3.91M | 8.68M |
| Accounts Payable | 7.12M | 2.13M | 2.59M | 635K | 635K | 1.34M |
| Days Payables Outstanding | 5.07K | - | - | - | - | - |
| Short-Term Debt | 730K | 730K | 730K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.97M | 2.9M | 2.2M | 1.98M | 0 | 417K |
| Current Ratio | 35.68x | 41.44x | 47.60x | 3.78x | 3.78x | 8.55x |
| Quick Ratio | 35.68x | 41.44x | 47.60x | 3.78x | 3.78x | 8.55x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 3.88M | 4.18M | 3.88M | 119.22M | 4.96M | 116.02M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 2.74M | 2.84M | 2.94M | 3.03M | 3.03M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.14M | 1.34M | 942K | 116.18M | 1.93M | 116.02M |
| Total Liabilities | 14.79M | 11.62M | 10.53M | 123.12M | 8.86M | 124.71M |
| Total Debt | 3.47M | 3.57M | 3.67M | 3.76M | 3.76M | 0 |
| Net Debt | -317.21M | -246.6M | -266.08M | -10.46M | -10.46M | -17.63M |
| Debt / Equity | 0.01x | 0.01x | 0.01x | - | 0.36x | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -25.64x | -25.64x | - |
| Total Equity | 378.69M | 301.31M | 310.22M | -103.87M | 10.39M | -50.45M |
| Equity Growth % | 3546.19% | - | - | - | 120.59% | - |
| Book Value per Share | 13.41 | 11.91 | 12.26 | -412.54 | 41.25 | -14.25 |
| Total Shareholders' Equity | 378.69M | 301.31M | 310.22M | -103.87M | 10.39M | -50.45M |
| Common Stock | 3K | 3K | 3K | 1K | 1K | 1K |
| Retained Earnings | -148.58M | -129.53M | -118.06M | -114.5M | -114.5M | -57.38M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 208K | 168K | -53K | 0 | 0 | 382K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |